Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

Meanwhile, Roche has started phase 3 trial of its IL-6 inhibitor Actemra/RoActemra (tocilizumab) in 330 hospitalised patients around the world.

FDA maintains COVID-19 therapeutics must meet a ‘gold standard’

s IL-6 inhibitor Actemra/RoActemra.
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace

of its Actemra/RoActemra (tocilizumab) in 330 hospitalised patients around the world.
China backs use of Roche’s Actemra for coronavirus

Actemra – which is sold as RoActemra in Europe – has been on the market since 2010 and was a $2bn-plus seller last year across its range of approved indications.
CAR-Ts Kymriah and Yescarta step closer to approval in Europe

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.
Roche's Actemra/RoActemra receives new European approval

GCA is a chronic and potentially life-threatening autoimmune condition and Actemra/RoActemra’s approval was based on data from the phase III GiACTA study. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to

More from news
Approximately 5 fully matching, plus 25 partially matching documents found.

Achieving remission

Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

The search for treatments for Parkinson’s disease: The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.: Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials: As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...